Source: International Congress 2019 – New Horizons in The Treatment of Pulmonary Fibrosis
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
T. Maher (St. Albans, United Kingdom). SSc-ILD: are we entering a new chapter in treatment?. International Congress 2019 – New Horizons in The Treatment of Pulmonary Fibrosis

Member's Comments

No comment yet.

Related content which might interest you: The pathogenesis of IPF: what is the latest paradigm? Source: International Congress 2019 – New Horizons in The Treatment of Pulmonary Fibrosis Year: 2019 The concept of control in COPD: a new proposal for optimising therapy Source: Eur Respir J 2014; 44: 1072-1075 Year: 2014 The paradoxes of asthma management: time for a new approach? Source: Eur Respir J, 50 (3) 1701103; 10.1183/13993003.01103-2017 Year: 2017 A network lung cancer pathway in review: Are we choosing the right diagnostic approach? Source: Annual Congress 2010 - Quality management for lung cancer patients Year: 2010 NORDSTAR: paving the way for a new era in asthma research Source: Eur Respir J, 55 (4) 1902476; 10.1183/13993003.02476-2019 Year: 2020 Towards the next stage of novel biomarker discussion in COPD: Tekizai-Tekisho Source: Eur Respir J 2014; 43: 322-324 Year: 2013 What next? Basic research, new treatments and a patient-centred approach in controlling tuberculosis Source: Eur Respir Monogr 2018; 82: 414-429 Year: 2018 The challenge of getting the right diagnosis: asthma and COPD, new diagnostic possibilities Source: International Congress 2016 – Primary Care Day: challenging times I Year: 2016 The new era of diagnostics: will it ever start? Source: International Congress 2019 – Fighting antimicrobial resistance: from prevention to antimicrobial stewardship Year: 2019 Who should receive which biologic and why? Current and future approaches in severe asthma patients Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what? Year: 2021 Pharmacological treatment optimisation for stable COPD: an endless story? Source: Eur Respir J, 50 (4) 1701250; 10.1183/13993003.01250-2017 Year: 2017 How are we going to treat IPF patients in the future? Source: Annual Congress 2013 –The future of IPF: current mysteries and challenges Year: 2013 Pharmacological options for the treatment of COPD: present and future Source: Annual Congress 2007 - PG6 - COPD: comprehensive clinical assessment and pharmacological and nonpharmacological therapy Year: 2007 Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence Source: Eur Respir Rev, 27 (150) 180074; 10.1183/16000617.0074-2018 Year: 2018 The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPF Source: Eur Respir J 2015; 46: 883-886 Year: 2015